http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0036087-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0a4b8d56488dbdbad2e3cc2e8dcde0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116e9052c728b37508de881cd0d4eae6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4713 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 1999-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32c9f3ecb682d0424b11329493e45eb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acae808b8300d23625f052eb992a093d |
| publicationDate | 2001-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0036087-A9 |
| titleOfInvention | Nucleolus autoantigenic marker for systematic lupus erythematosus |
| abstract | A novel nucleolus protein has been identified and cloned using human autoimmune serum. Its cDNA and amino acid sequences have been determined and are disclosed. This antigenic protein, termed ASE-1 has an approximate molecular mass of 55 kDa. Immunoblot analysis indicates that both the native protein and the in vitro translation products of the cDNA migrate on SDS-PAGE at an apparent molecular mass of 90 kDa. Indirect immunofluorescence analysis using antibodies generated to cloned regions of ASE-1 indicates that this protein occurs at the fibrillar centers of the nucleolus in the putative sites of rDNA transcription. During cell division ASE-1 localizes to the nucleolus organizer regions of the chromosomes, where it is closely associated with RNA polymerase 1. As an autoantigenic nucleolar protein, ASE-1 has been found to be a reliable serum marker for systemic lupus erythematosus (SLE). This finding makes ASE-1 useful in the clinical detection and characterization of the disease. To identify the presence of SLE in an individual patient, a serum sample is taken and screened against the cloned ASE-1 protein to identify sera with anti-ASE-1 autoantibodies. This screening can be done using an ELISA assay, western blot techniques, or by binding the antigen to microspheres and identifying reactive sera by flow cytometry. |
| priorityDate | 1998-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.